Although several new small-molecule inhibitors have been developed (e.g., ABT-199, midostaurin, and IDH1/2 inhibitor) and have shown promising results in R/R AML treatment, they are not currently commercially available in mainland China. The gene discussed is IDH1; the disease is acute myeloid leukemia.